Revance Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Revance Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2018 to Q2 2024.
  • Revance Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $49.7M, a 44.5% increase year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $49.7M +$15.3M +44.5% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $70.2M +$32.3M +85.3% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $53.2M +$13.9M +35.6% Dec 31, 2023 10-Q 2024-08-08
Q3 2023 $54.8M +$14.3M +35.3% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $34.4M -$7.36M -17.6% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $37.9M -$5.15M -12% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $39.2M -$5.12M -11.5% Dec 31, 2022 10-K 2024-02-28
Q3 2022 $40.5M -$5.01M -11% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $41.8M -$4.53M -9.78% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $43.1M +$14.3M +49.6% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $44.3M +$14.7M +49.6% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $45.5M +$20.1M +78.9% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $46.3M +$21M +82.7% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $28.8M +$2.82M +10.9% Mar 31, 2021 10-Q 2021-05-10
Q4 2020 $29.6M +$3.1M +11.7% Dec 31, 2020 10-K 2022-02-28
Q3 2020 $25.4M -$1.63M -6.03% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $25.4M -$2.24M -8.1% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $26M -$2.14M -7.63% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $26.5M +$26.5M Dec 31, 2019 10-K 2021-02-25
Q3 2019 $27.1M Sep 30, 2019 10-Q 2019-11-04
Q2 2019 $27.6M Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $28.1M Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $0 Dec 31, 2018 10-K 2020-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.